Market Research Logo

Mesenchymal Stem Cells - Advances & Applications

Mesenchymal Stem Cells – Advances & Applications

BioInformant, the only market research firm to exclusively serve the stem cell sector, announces the release of its global strategic report, “Mesenchymal Stem Cells – Advances and Applications.” Published November 2015, it presents 250 pages of coverage for the rapidly-evolving mesenchymal stem cell (MSC) industry.

Called the "most innovative market research firm in the world,” BioInformant tracks MSC industry metrics using continuously maintained dashboards combined with systems to trigger alerts when data exhibits unexpected variation.

A unique attribute of BioInformant is that its management team comes from a BioInformatics background – the science of collecting and analyzing complex biological data. BioInformant is the only known research firm to apply these data analysis techniques to the field of market research. This is important, because 2015 saw the first “thaw and use” ink to make MSCs readily available for 3D printing (RoosterBio and CELLINK), a novel manufacturing approach to produce a nearly unlimited supply of MSCs from iPSCs derived from a single donor (Cynata Therapeutics), and the recommendation for approval of a MSC product in Japan (JR-031 developed by Mesoblast's Japanese partner, JCR Pharmaceuticals Co. Ltd). It is clear that the scope of the MSC industry is expanding and advanced analytics are required.

In addition, the report describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine industry and overall cell therapy industry.

The report also explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace. For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

BioInformant has a Decade of Historical Data and Utilizes Continuously Maintained Dashboards

Founded in 2006 in Washington, DC, BioInformant is distinctively suited to tracking the MSC industry, because it has been following the industry for a decade, providing a robust database of historical data.

Importantly, BioInformant is always innovating. It tracks traditional market metrics, which include trend rate data for MSC clinical trials, scientific publications, grants, patents, product launches, new market entrants, industry acquisitions, collaborations, and more. However, it also tracks recently discovered social analytics, which are metrics derived from social media sites, search engines, online advertising platforms, and more. It is the only known research firm to take this duel-approach to market analysis.

Another unique attribute of BioInformant is that its management team comes from a BioInformatics background – the science of collecting and analyzing complex biological data. BioInformant is the only known research firm to apply these data analysis techniques to the field of market research.

BioInformant research has been cited on prominent news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, the Center for BioNetworking, and more. BioInformant serves notable clients across the stem cell spectrum, with Fortune 500 companies on its client list including GE Healthcare, Pfizer, Goldman Sachs, Beckton Dickinson, and many more.

Opportunities for Commercializing Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. They are advantageous over other stem cells types for a variety of reasons. They avoid the ethical issues that surround embryonic stem cell research, and repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogenic transplantation. MSCs also being explored for use in 3D printing applications, because of their unique capacity to form structural tissues.

Because MSCs represent a valuable market segment, stem cell executives and investors must to have a clear understanding of opportunities and threats occurring within the marketplace. As the technology surrounding MSC production has advanced, novel approaches to MSC manufacturing have emerged. As clinical trials investigating MSCs have increased in number, new companies have entered the marketplace to explore clinical applications.

Other emerging threats that could impact the MSC industry include inconsistent or negative clinical findings, competing technologies, and the potential for other stem cell types to provide better efficiency or function. Fluctuating government perspectives on whether the manipulation of stem cells prior to transplantation into humans should be allowed is also a current “hot topic” among regulatory bodies within the U.S. and other regions worldwide, with such legislation affecting the Regenexx® technology and other therapeutic applications involving MSCs.

However, there is also great potential for growth of the MSC market, with more than 30,000 scientific publications published about the cell type, more than 400 clinical trials underway worldwide, and Google Trend data showing MSC searches to be more than twice as common as the next most popular stem cell type.

Therefore, the main objectives of the report are to consider the following:

  • Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular
  • Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells
  • Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types
  • The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their ongoing search for MSCs-based cell therapy products
  • Analysis of traditional market metrics (grant rates, clinical trial rates, patent rates, scientific publication rates) and new social analytics (metrics from social media sites, search engines, Google Trends, and more)
Key questions answered in the report are:(Regenerative Medicine = RM; Cell Therapy= CT)
  • How many companies are currently supporting the regenerative medicine (RM) industry?
  • What is the current regional breakdown of RM industry?
  • How many RM products have been approved?
  • What are the types of diseases are currently being pursued by RM companies?
  • What are the major financial events, partnerships and acquisitions in RM sector?
  • How do the large pharma companies perceive the value and long-term prospects of RM and cell therapy (CT)?
  • What are the major anticipated RM clinical events in 2015-16?
  • What are the major therapeutic opportunities for the big pharma in RM and CT?
  • How many CT product candidates have reached the Phase III stage and what are they?
  • What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
  • What are the major commercially available CT products?
  • What is the total number of CT clinical trials at the global level?
  • What are the major cell types used in CT clinical trials?
  • What are the major indications addressed by CT clinical trials?
  • What are the major CT clinical trials that have reached Phase III?
  • How many CT clinical trials failed in the past year and what are they?
  • What are the contributions of MSCs to the cell therapy industry?
  • What are the biological properties of MSCs?
  • What do MSCs get differentiated into?
  • What bioactive molecules do the MSCs secrete?
  • What are the immunomodulatory functions of MSCs?
  • What are the factors impacting the acquisition of MSCs?
  • What are the various sources of MSCs?
  • What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
  • What are the major clinical trials focusing on diabetes using BMMSCs?
  • What are the major clinical trials involving BMMSCs for cardiovascular diseases?
  • What are the major clinical trials focusing on liver diseases by BMMSCs?
  • What are the brain-related diseases addressed by clinical trials using BMMSCs?
  • How many clinical trials are conducted for intestinal diseases using MSCs?
  • What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
  • Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
  • What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
  • What is the current number of clinical trials using MSCs?
  • How many major clinical trials using MSCs have reached the Phase III?
  • What are the MSCs-based cell therapy products available in the market?
  • What is the current size of the MSC marketplace
About BioInformant

Founded in 2006 in Washington, DC, BioInformant is the only market research firm to serve the stem cell sector since it emerged. A unique attribute of BioInformant is that our management team comes from a BioInformatics background – the science of collecting and analyzing complex biological data – and we apply these techniques to the field of market research. Called the "most innovative market research firm in the world,” BioInformant has been featured on prominent news outlets including the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, the Center for BioNetworking, and more. In addition to offering cutting-edge stem cell market intelligence, BioInformant operates a stem cell industry blog at www.BioInformant.com which is nearing 100K views per month and has a subscriber base of stem cell industry executives and investors approaching 10K. It is a company goal to reach 500K views by mid-2017. BioInformant’s President/CEO, Cade Hildreth, acts as a media expert on stem cell industry topics, recently conducting interviews with the Wall Street Journal and Los Angeles Business Journal.

The content and metrics contained in this report were compiled using a broad range of sources, including:
  • Stem Cell Grant Databases (RePORT Database, CIRM, MRC, Wellcome Trust - UK)
  • Stem Cell Patent Databases (United States Patent and Trade Office, World Intellectual Property Organization)
  • Stem Cell Clinical Trial Databases (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register )
  • Stem Cell Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)
  • Stem Cell Product Launch Announcements (Trade Journals, Google News)
  • Stem Cell Industry Events (Google News, Google Alerts)
  • Stem Cell Company News (SEC Filings, Investor Publications, Historic Performance)
  • Interviews with Stem Cell Industry Leaders and Executives
  • SEC Filings and Related Investor Publications
  • Social Analytics Tools for Twitter, LinkedIn, Google Search, Google Trends, and More
  • BioInformant’s Proprietary Dashboard of MSC Industry Metrics and 10-Year Historical Database
Key findings within this report include:
  • Trend rate data for MSC grants, clinical trials, scientific publications, and patents
  • Recent advances in MSC research and clinical applications
  • Market size determinations, including future projections through 2020
  • Deal-making within the MSC marketplace, including key acquisitions and partnerships
  • Competitive assessment of the MSC marketplace, by market segment
  • Research priorities by market segment
  • Top influencers with the MSC marketplace
  • Social analytics for the MSC marketplace
  • Twitter User Data, Google Trends User Data, Google Adwords Costs, and Hashtag
  • Overview of the broader regenerative medicine (RM) and cell therapy (CT) marketplace
  • Company profiles for 35 MSC industry leaders


Executive Summary

Mesenchymal stem cells (MSCs) are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, other cell types. MSCs are of intense therapeutic interest, because they represent a population of cells with the potential to treat a range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation. Because of their unique capacity to form structural tissues, MSCs also being explored for use in 3D printing applications.

The report describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine (RM) and cell therapy (CT) industries.

It also explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace. For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

There is substantial potential for growth within the MSC market, with more than 30,000 scientific publications published about the cell type, more than 400 clinical trials underway worldwide, and Google Trend data showing MSC searches to be approximately twice as common as the next most common adult stem cell type.

Therefore, the main objectives of the report are to consider the following:

  • Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular
  • Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells
  • Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types
  • The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their ongoing search for MSCs-based cell therapy products
  • Analysis of traditional market metrics (grant rates, clinical trial rates, patent rates, scientific publication rates) and social analytics (metrics from social media sites, search engines, Google Trends, Google Adwords, and more)
Key questions answered in the report are: (Regenerative Medicine = RM; Cell Therapy= CT)
  • How many companies are currently supporting the regenerative medicine (RM) industry?
  • What is the current regional breakdown of RM industry?
  • How many RM products have been approved?
  • What are the types of diseases are currently being pursued by RM companies?
  • What are the major financial events, partnerships and acquisitions in RM sector?
  • How do the large pharma companies perceive the value and long-term prospects of RM and cell therapy (CT)?
  • What are the major anticipated RM clinical events in 2015-16?
  • What are the major therapeutic opportunities for the big pharma in RM and CT?
  • How many CT product candidates have reached the Phase IIIstage and what are they?
  • What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
  • What are the major commercially available CT products?
  • What is the total number of CT clinical trials at the global level?
  • What are the major cell types used in CT clinical trials?
  • What are the major indications addressed by CT clinical trials?
  • What are the major CT clinical trials that have reached Phase III?
  • How many CT clinical trials failed in the past year and what are they?
  • What are the contributions of MSCs to the cell therapy industry?
  • What are the biological properties of MSCs?
  • What do MSCs get differentiated into?
  • What bioactive molecules do the MSCs secrete?
  • What are the immunomodulatory functions of MSCs?
  • What are the factors impacting the acquisition of MSCs?
  • What are the various sources of MSCs?
  • What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
  • What are the major clinical trials focusing on diabetes using BMMSCs?
  • What are the major clinical trials involving BMMSCs for cardiovascular diseases?
  • What are the major clinical trials focusing on liver diseases by BMMSCs?
  • What are the brain-related diseases addressed by clinical trials using BMMSCs?
  • How many clinical trials are conducted for intestinal diseases using MSCs?
  • What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
  • Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
  • What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
  • What is the current number of clinical trials using MSCs?
  • How many major clinical trials using MSCs have reached the Phase III?
  • What are the MSCs-based cell therapy products available in the market?
  • What is the current size of the MSC marketplace?
35 leading MSC companies are profiled in this report, including:
  • American Type Culture Collection Inc. (ATCC)
  • Anterogen Co., Ltd.
  • Apceth GmbH & Co. KG
  • BioCardia Inc.
  • BioRestorative Therapies Inc.
  • Bone Therapeutics SA
  • BrainStorm Cell Therapeutics Inc.
  • CellGenix Technologie Transfer GmbH
  • Celprogen Inc.
  • CellTherapies P/L
  • Cesca Therapeutics Inc.
  • Cyagen Biosciences Inc.
  • Cynata Therapeutics Ltd.
  • Cytori Therapeutics Inc.
  • Escape Therapeutics
  • Genlantis
  • Kite Pharma Inc.
  • Life Technologies Corporation
  • Lonza Group Ltd.
  • Medipost Co. Ltd.
  • Mesoblast Ltd.
  • NuVasive Inc.
  • Ocata Therapeutics Inc.
  • Organogenesis Inc.
  • Orthofix International N.V.
  • Osiris Therapeutics Inc.
  • Pluristem Therapeutics Inc.
  • PromoCell
  • Regeneus Ltd.
  • ScienCell Research Laboratories
  • STEMCELL Technologies Inc.
  • Stemedica Cell Technologies Inc.
  • Stempeutics Research Pvt. Ltd.
  • TiGenix N.V.
  • Vericel Corporation

  • EXECUTIVE SUMMARY
  • REPORT OVERVIEW
    • Target Demographic
    • Key Findings
    • Statement of the Report
    • Purpose
      • To Survey Recent MSC Advancements
      • To Provide a "Snapshot" of the Global MSC Market
      • To Assess Opportunities for Commercialization
      • To Identify Major Market Players and Assess the Competitive Environment
      • To Identify Existing and Emerging Trends
      • To Identify Critical Opportunities and Threats within the MSC Market
  • RESEARCH METHODOLOGY
    • Input Sources
    • Research & Analysis Methodologies
    • Criteria for Identiyfing MSC Market Leaders
  • MESENCHYMAL STEM CELL (MSC) DEFINITIONS & NOMENCLATURE
    • Definition
    • Alternative Nomenclature
      • Mesenchymal Stem Cell
      • Marrow Stromal Cell / Mesenchymal Stromal Cell
      • Multipotent Stromal Cell
      • Colony-Forming Unit-fibroblasts
  • CRITERIA & CHARACTERISTICS
    • Discovery
    • Physical Assessment
    • Functional Attributes
    • Benefits of MSCs Relative to Other Stem Cells
      • Well-Characterized
      • Non-Controversial
      • Diverse Differentiation Potential
      • Ease of Growth in Culture
      • Flexible Propagation
      • Clinically Relevant Volumes
      • Role as Regulatory Cells
      • Delivery of Gene Products
      • Favorable Immune Status
      • Commercially Available Research Tools
  • MSC ISOLATION SOURCES
    • Adult Sources
      • Table Adult Sources for Mesenchymal Stem Cell (MSC) Isolation
    • Fetal Sources
      • Table Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation
  • COMMERCIAL INTEREST IN MSCs
    • Cell Types Derived from MSCs
      • Table Differentiation Capacity of Mesenchymal Stem Cells
    • Therapeutic Potential of MSCs
  • INTRODUCTION TO REGENERATIVE MEDICINE (RM) INDUSTRY
    • Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview
    • Global Breakdown of Regenerative Medicine (RM) Industry by Region
      • Table Global Breakdown of RM Companies by Region
    • Breakdown of Global Regenerative Medicine (RM) Companies by Type
      • Table Global Breakdown of RM Companies by Type
    • Number of RM Clinical Trials by Phase of Development
      • Table Number of RM Clinical Trials by Phase
    • Major Financial Events in the RM Industry
      • Table Major Financial Events in RM Industry in 2014
    • Major Partnerships and Acquisitions in RM Industry
      • Table Major Partnerships and Acquisitions in RM Industry in 2014
    • Major Regulatory Milestones in RM Industry
      • Table Major Regulatory Milestones in RM Industry in 2014
    • Major Pharma and Biotech Companies Active in Advanced Therapies
      • Table Major Pharma and Biotech Companies Active in Advanced Therapies
      • Table Areas of Focus among Large Pharmaceutical and Biotech Companies Involved with Advanced Therapies
    • Major Corporate Partnerships in RM Industry
      • Table Major Corporate Partnerships in RM Industry in 2014
    • Anticipated Major RM Clinical Events
      • Table Anticipated Major RM Clinical Events in 2015
  • STEM CELL THERAPY INDUSTRY: A BRIEF OVERVIEW
    • Types of Stem Cells Used in Cell Therapy
      • Human Embryonic Stem Cells
      • Induced Pluripotent Stem Cells
      • Mesenchymal Stem Cells (MSCs)
      • Hematopoietic Stem Cells
      • Adipose Stem Cells (ASCs)
      • Neural Stem Cells (NSCs)
        • Table Different Types of Stem Cells Used in Cell Therapy and their Characteristics
    • Types of Stem Cells Used in Cell Therapy, by Differentiation Potential
      • Totipotent (or Omnipotent) Stem Cells
      • Pluripotent Stem Cells
      • Multipotent Stem Cells
      • Oligopotent stem cells
      • Unipotent Stem Cells
  • CELL THERAPY PRODUCTS: SUCCESSES AND FAILURES
    • Cell Therapy Product Candidates in Late-Stage Clinical Development
      • Table Mesenchymal Stem Cell Product Candidates in Late-Stage Clinical Development
    • Cell Therapy Products Being Developed for Cardiovascular Indication
    • Cell Therapy Products Being Developed for Other Indications
    • Major Commercially Available Cell Therapy Products
    • Cell Therapy Products Approved in South Korea
      • Table Cell Therapy Products Approved in South Korea
    • Major Cell Therapies in Phase III
      • Prochymal
      • Mesenchymal Precursor Cell (MPC)
      • MyoCell
      • Ixmyelocel-T
      • ELAD
      • HP802
      • StemEx (Carlecortemcel-L)
      • LaViv
      • GSK 2696273
      • Renew
      • NT-501 (Renexus)
      • Neocart
      • DeNovo ET
      • MACI
    • Clinical Trial Failures in Cell Therapy
      • Failure of Phase II for MultiStem
      • Failure of Cardio 133 Trial
      • Termination of AlloCure's ACT-AKI Trial
      • Failed Stroke Trial in India
      • Failure of HeartiCellGram-AMI Trial
      • Failure of Adipose MSCs in ARDS
      • CD133+ in CLI Not Feasible
      • Failed MSC Trial for Multiple Sclerosis
      • Failure of Chinese Diabetes Trial
      • Failed Efficacy Trial in AMI by Stempeucel
      • Involvement of Multinational Companies (MNCs) in Cell Therapy Sector
        • Table Major Companies and Products in Development within the Cell Therapy Sector
  • THE MARKET FOR STEM CELL THERAPIES
    • Market Potential - All Stem Cell Types
    • Market Potential - Mesenchymal Stem Cells
    • Global Market for Stem Cells by Disease Indication
      • Table Global Market for Stem Cell Therapies by Disease Indication, Through 2021
  • MESENCHYMAL STEM CELL APPLICATIONS
    • Table MESENCHYMAL STEM CELL RESEARCH APPLICATIONS
    • Basic Research Applications
      • MSC Morphology
      • MSC Detection
      • Differentiation Capacity:
      • Immuno-modulatory Effects
    • Cell Transplantation for Site-Specific Repair
      • Osteochondral Repair
      • Myogenic and Myocardial Repair
      • Neural Repair
      • Pancreatic Repair
    • Directed Differentiation of Mesenchymal Stem Cells
      • Directed Differentiation of Mesenchymal Stem Cells into Intra-Mesenchymal Lineages
      • Directed Differentiation of MSCs into Extra-Mesenchymal Lineages
    • Drug Delivery Applications: Engineered MSCs as Carriers of Anti-Cancer Drugs
    • Drug Screening
    • Gene Transfer Studies
    • MSC-Mediated Inhibition of Immune Effector Cells
    • Supporting Hematopoietic Cell Applications
    • Use of 3-D Scaffolds for Tissue Engineering
    • Topical Therapy and Use of MSCs in Wound Healing
  • MSC PRODUCT DEVELOPMENT VARIABLES - ATTRIBUTES & ACQUISITION
    • Biological Properties of MSCs Contributing to Therapeutic Effects
      • MSCs' Capacity to Migrate and Engraft
      • MSCs' Differentiation Potential
        • Table Origin and Cell Types Derived from MSCs
      • MSCs' Potential to Secrete Multiple Bioactive Molecules
        • Table Important Bioactive Molecules Secreted by MSCs and Their Functions
      • MSCs' Potential for Immunomodulatory Functions
        • Table Immunomodulatory Effects of MSCs on Immune Cells
      • Variable Immunophenotype of MSCs
        • Table Cell Surface Antigen Expressions of MSCs Isolated from Different Sources
    • Factors Impacting MSCs Acquisition
    • Major Clinical Sources of MSCs
      • Table Major Clinical Sources of MSCs
  • CLINICAL APPLICATIONS OF MESENCHYMAL STEM CELLS
    • Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs)
      • BMMSCs and Kidney
        • Table A Sample of Clinical Trials using BMMSCs for Kidney Diseases
      • BMMSCs and Pancreas
        • Table A Sample of Clinical Trials Using BMMSCs for Diabetes
      • BMMSCs and Heart
        • Table A Sample of Clinical Trials Using BMMSCs for Heart Disease
      • BMMSCs and Liver
        • Table A Sample of Clinical Trials Using BMMSCs for Liver Diseases
      • BMMSCs and Brain
        • Table Clinical and Experimental Therapies Using MSCs for Neural Diseases
      • BMMSCs and Intestine
        • Table A Sample of Clinical Trials Using BMMSCs for Intestinal Diseases
      • BMMSCs and Bone
        • Table A Sample of Clinical Trials Using BMMSCs for Musculoskeletal Diseases
    • Adipose-Derived Mesenchymal Stem Cells (ADSCs)
      • Clinical Appplicationsof Adipose-Derived Mesenchymal Stem Cells (ADSCs)
        • Table ADSCs Transplantation in Clinical Trials by Region/Country in Phase III
      • Selected ADSC Secretomes and their Functions
        • Table Selected ADSC Secretomes and their Functions
    • Mesenchymal Stem Cells (MSCs) Derived from Wharton's Jelly
      • Clinical Application Properties of WJ-MSCs
      • Immunoprivileged Status of WJ-MSCs
      • Clinical Applications of WJ-MSCs
        • Table A Summary of Clinical Trials Using WJ-MSCs
    • Umbilical Cord Blood-Derived MSCs (UCBMSCs)
      • Table Clinical Trials Using UCBMSCs and Targeted Diseases
    • Dominance of MSCs in Cell Therapy Clinical Trials
  • MAJOR DISEASES ADDRESSED BY MSCs IN CURRENT CLINICAL TRIALS
    • Table Clinical Trials Using MSCs by Disease Type, 2014
    • MSCs for Treating Liver Diseases
      • Table A Sample of Clinical Trials Using MSCs for Liver Disorders
    • MSCs for Neurodegenerative Diseases
      • Table A Sample of Clinical Trials Using MSCs for Neurodegenerative Diseases
    • Clinical Trials Using MSCs for Autoimmune Diseases
      • Table A Sample of Phase I and II Clinical Trials for Autoimmune Diseases as of 2012
    • Clinical Trials Using MSCs for Diabetes
      • Table A Sample of Clinical Trials Using MSCs for Diabetes
    • MSCs for Cardiovascular Repair
      • Table A Sample of Clinical Trials Using MSCs for Cardiovascular Diseases
    • MSCs for Musculoskeletal Diseases
      • Table Clinical Trials Involving MSCs for Bone and Cartilage Repair
      • Studies Using MSCs for Musculoskeletal Indications by Leading Countries
        • Table Studies Using MSCs for Musculoskeletal Indications by Country
      • Application of MSCs in Joint Diseases
        • Table A Sample of Current Clinical Trials Using MSCs for Osteoarthritis
        • Table A Sample of Clinical Trials Involving MSCs for Bone and Cartilage Repair
    • MSCs in Neuron/Spinal Cord Diseases
      • Table A Sample of Clinical Trials in Different Countries Using MSCs for Neuron and Spinal Cord Diseases
    • MSC Infusion for GvHD
      • Table Clinical Experience of MSCs in GvHD Treatment
    • MSCs for Crohn's Disease
      • Table A Sample of Clinical Trials Using MSCs for Crohn's Disease
    • MSCs in Wound Healing
      • Table Clinical Studies using MSCs for Wound Healing
    • Increasing Focus on Immunological Properties of MSCs
      • Table Number of MSC Scientific Publications about Immune/Inflammation by Year
    • Selected MSCs Late-Stage Pipeline Cell Therapies
      • Table Selected MSCs Late-Stage Pipeline Cell Therapies
  • MARKET OPPORTUNITIES FOR BIOBANKING OF MESENCHYMAL STEM CELLS
    • Types of Mesenchymal Stem Cell Biobanking
      • Table Types of Mesenchymal Stem Cell Biobanking
    • Dental Stem Cell Banking (MSC Biobanking)
      • Table Companires Offering Dental Stem Cell Storage (Diversified Cord Blood Banks and Specialty Companies)
    • Umbilical Cord Tissue (MSC Biobanking)
      • Definitions
      • Cord Tissue Market Overview
      • Comparison of Cord Blood & Cord Tissue Storage
      • Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CTMSCs)
        • Table Medical Conditions Being Investigated for their Potential to be Treated with Cord Tissue Derived from Mesenchymal Stem Cells
      • Market Penetration of Cord Tissue Storage within the U.S.
        • Table U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013
        • Table U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015
      • Pricing of Cord Tissue Storage (Global Analysis)
        • Table Pricing Structures for Cord Tissue Storage
    • Adipose-Derived MSCStorage
      • Table Companies Offering Adipose-Derived MSC Storage (Both Diversified Cord Blood Banks and Specialty Companies)
    • Other Types of MSCBio-Banking: Placental Tissue, Menstrual Stem Cells, Peripheral Blood Stem Cells, Bone Marrow Stem Cells, and More
  • MESENCHYMAL STEM CELL (MSC) MARKET METRICS
    • Global Breakdown of Mesenchymal Stem Cell Clinical Trials
      • Breakdown of MSC Clinical Trials, By Phase
      • Additional Resources
      • Breakdown of MSC Clinical Trials By Geography
        • Table Geographical Breakdown of MSC Clinical Trial Activity
      • Types of Sponsoring/Collaborating Organizations Supporting MSC Clinical Trials
        • Table Breakdown of MSC Clinical Trial Activity by Sponsoring/Collaborating Organization
      • Specific Industry Participants Supporting MSC Clinical Trial Activity
        • Table Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
        • Table Top 4 Industry Participants Sponsoring/Collaborating on MSC Clinical Trials
      • Summary of Findings for Mesenchymal Stem Cell Clinical Trials
    • MSC Patent Analysis
      • Role of Patent Analysis for Competitive Intelligence
      • MSC Patent Landscape
      • Methodology of MSC Patent Analysis
      • MSC Patents Filed in 2015
        • Table Mesenchymal Stem Cell Patents Filed in 2015
    • Scientific Publication Analysis
      • Table Analysis of MSC Scientific Publications per Year
    • MSC Grant Rate Analysis
      • All-Time Analysis of MSC Grants (1997 to Present)
        • Table Number of MSC Grant Rates by Year (RePORTer Analysis)
        • Table Number of MSC Projects Funded by NIH Support by Year
        • Table Amount of Funding for MSC Projects Supported by NIH by Year (In Millions)
        • Table Geographical Assessment of MSC Grants Funded by NIH-Support
        • Table LEADING PRINCIPAL INVESTIGATORS FOR MSC RESEAERCH, BY NUMBER OF PROJECTS
      • 2015 Analysis of MSC Grants
        • Table MSC Grants Funded by NIH-Support in 2015 Fiscal Year (RePORTer Analysis)
        • Table Breakdown of MSC Grants Funded by NIH-Support by Subject (Circle Map)
  • SOCIAL ANALYTICS FOR MESENCHYMAL STEM CELLS
    • Marketing Cost Analysis for MSCs
      • Pay-Per-Click Cost for MSCs
        • Table Google Adwords Pay-Per-Click (PPC) Costs for MSCs
    • MSC Articles Receiving Most Social Media Shares over Past 12 Months
      • MSC Specific Analysis
        • Table Most Shared MSC Articles of the Past 12 Months
      • Stem Cell Analysis (All Types)
        • Table Most Shared Stem Cell Articles of the Past 12 Months (All Stem Cell Types)
    • Google Trend Data for MSCs
      • Google Trend Data - Mesenchymal Stem Cells Only
        • Table Google Trend Data Showing Related Searches for "Mesenchymal Stem Cells"
      • Google Trend Data - All Types of Stem Cells
        • Table Google Trend Data Showing Related Searches for "Mesenchymal Stem Cells"
    • Twitter Hashtag Data
      • Table Rates of Twitter Usage by Country
      • Twitter Hashtag Data - Mesechymal Specific Data
        • Table Top 10 Hashtags Related to "#Mesenchymal" on Twitter
      • Twitter Hashtag Data - Stem Cells (All Types)
        • Table Top 10 Hashtags Related to the Term "#StemCells" on Twitter
      • Top Five MSC Influencers on Twitter
        • Table Top 5 MSC Influencers on Twitter
      • Top Five Stem Cell Influencers on Twitter
        • Table Top 5 Stem Cell Influencers on Twitter
  • SELECTED COMPANY PROFILES
    • American Type Culture Collection Inc. (ATCC)
    • Anterogen Co., Ltd.
      • Cupistem Injection
      • Queencell
    • Apceth GmbH & Co. KG
      • Apceth's Research Areas
    • BioCardia Inc.
      • Table BioCardia's Product Pipeline Overview
    • BioRestorative Therapies Inc.
      • brtxDISC
      • ThermoStem
    • Bone Therapeutics SA
      • PREOB
      • ALLOB
        • Table Bone Therapeutics' Product Pipeline
    • BrainStorm Cell Therapeutics Inc.
      • NurOwn
    • CellGenix Technologie Transfer GmbH
    • Celprogen Inc.
    • CellTherapies P/L
      • Services
      • Product
    • Cesca Therapeutics Inc.
      • Surgwerks
      • Cellwerks
      • AutoXress (AXP)
      • MarrowXpress (MXP)
      • Res-Q BMC
    • Cyagen Biosciences Inc.
      • Mesenchymal Stem Cells from Cyagen
        • Table Cyagen's Mesenchymal Cells
      • Adipose-Derived Mesenchymal Stem Cells from Cyagen
        • Table Cyagen's Adipose-Derived MSCs
      • Mesenchymal Stem Cells with GFP from Cyagen
        • Table Gyagen's MSCs with GFP
      • Adipose-Derived Mesenchymal Cells with GFP from Cyagen
        • Table Adipose-Derived Mesenchymal Cells with GFP
      • Stem Cell Culture Media from Cyagen
        • Table Cyagen's Stem Cell Culture Media
      • Stem Cell Differentiation Media from Cyagen
        • Table Cyagen's Stem Cell Differentiation Media
      • Primary Cells from Cyagen
        • Table Primary Cells from Cyagen
      • Cyagen's Cryopreservation Media
        • Table Cyagen's Cryopreservation Media
      • Cyagen's Primary Cell Culture Media
        • Table Cyagen's Primary Cell Culture Media
      • General Cell Culture Supplements and Specialty Reagents from Cyagen
        • Table General Cell Culture Supplements and Specialty Reagents from Cyagen
    • Cynata Therapeutics Ltd.
      • Cymerus Platform Technology
    • Cytori Therapeutics Inc.
      • Clinical Trial for Scleroderma
      • Clinical Trials for Osteoarthritis
    • Escape Therapeutics
      • Table Escape Therapeutics' Pipeline Products
    • Genlantis
    • Kite Pharma Inc.
      • Engineered Autologous Cell Therapy (eACT)
      • DC-Ad GM-CAIX
        • Table Kite Pharma's Pipeline and Clinical Trials
    • Life Technologies Corporation
    • Lonza Group Ltd.
      • Selected Products
    • Medipost Co. Ltd.
      • Cartistem
      • Neurostem
      • Pneumostem
    • Mesoblast Ltd.
      • Mesoblast's Product Pipeline Overview
        • Table Mesoblast's Product Pipeline Overview
    • NuVasive Inc.
      • Osteocel
    • Ocata Therapeutics Inc.
      • Table Ocata's Pipeline of Therapeutic Programs
    • Organogenesis Inc.
      • Apligraf
      • Dermagraft
    • Orthofix International N.V.
      • Trinity Elite
      • Trinity Evolution
    • Osiris Therapeutics Inc.
      • Grafix
      • OvationOS
      • Cartiform
    • Pluristem Therapeutics Inc.
      • PLX Cells
    • PromoCell
    • Regeneus Ltd.
      • Products
        • Table Regeneus' Product Pipeline
    • ScienCell Research Laboratories
    • STEMCELL Technologies Inc.
    • Stemedica Cell Technologies Inc.
      • Stemedyne MSC
      • Stemedyne NSC
      • Stemedyne RPE
    • Stempeutics Research Pvt. Ltd.
      • Stempeucel
      • Stempeutron
      • Stempeucare
        • Table Stempeucel in Clinical Trials by Indication
    • TiGenix N.V.
      • Cx601
      • Cx611
      • Cx621
    • Vericel Corporation
      • Table Vericel Corporation's Product Portfolio
      • Table Summary Table for the Companies and Their Product Types

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report